CytoMed Therapeutics (GDTC) announced that it has submitted a cash bid for an undisclosed sum with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP who were appointed as joint administrators to TC BioPharm Limited on October 2, 2025, in relation to a potential acquisition of potentially synergistic assets of TCBL. TCBL and CytoMed are both clinical stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment. TCBL has completed Phase I clinical trial, while CytoMed is currently conducting its Phase I ANGELICA Trial in Singapore under an Investigational New Drug application, evaluating its proprietary chimeric antigen receptor T cells for a broad range of liquid and solid cancers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDTC:
- CytoMed Therapeutics Unveils Promising AML Therapy Research
- Cytomed Therapeutics announces publication of research on T cells
- CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges
- CytoMed Therapeutics Expands into Auto-immune Diseases with Cord Blood Biotech
- Cytomed Therapeutics expanded into auto-immune diseases